ANALIZ VLIYaNIYa FIBROZA PEChENI NA EFFEKTIVNOST' I BEZOPASNOST' ANTIKhELIKOBAKTERNOY TERAPII
- 作者: Andreev D.N1, Maev I.V1, Dicheva D.T1, Kucheryavyy Y.A1, Partsvania-Vinogradova E.V1
-
隶属关系:
- 期: 编号 20 (2015)
- 页面: 69-71
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288402
- ID: 288402
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The article presents the results of a prospective clinical study aimed to the evaluation of the efficacy and safety of anti-Helicobacter therapy (AHT) in patients with concomitant chronic hepatitis C, depending on the stage of liver fibrosis. The data obtained allow to conclude that the effectiveness of AHT is not significantly dependent on the stage of liver fibrosis, but the presence of fibrosis significantly determines the risk of side effects on the background of the AHT. The group of highest risk includes patients with liver cirrhosis.
全文:
作者简介
D. Andreev
Email: dna-mit8@mail.ru
I. Maev
D. Dicheva
Yu. Kucheryavyy
E. Partsvania-Vinogradova
参考
- Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М., 2015.
- Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Тер. архив. 2014; 3: 94-9.
- Malfertheiner P., Megraud F., O'Morain C., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P.,Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J.;. Management of Helicobacter pylori infection - Maastricht IV. Florence Consensus Report Gut. 2012; 61: 646-64.
- El-Masry S., El-Shahat M., Badra G., Aboel-Nour M.F., Lotfy M. Helicobacter pylori and Hepatitis C Virus Coinfection in Egyptian Patients. J. Glob. infect. Dis. 2010; 2(1): 4-9.
- Furusyo N., Walaa A.H., Eiraku K., Toyoda K., Ogawa E., ikezaki H., Ihara T., Hayashi T., Kainuma M., Murata M., Hayashi J. Treatment for Eradication of Helicobacter pylori infection among Chronic Hepatitis C Patients. Gut. Liver. 2011; 5(4): 447-53.
- Ponzetto A., Pellicano R., Redaelli A., Rizzetto M., Roffi L. Helicobacter pylori infection in patients with Hepatitis C Virus positive chronic liver diseases. New Microbiol. 2003; 26(4): 321-28.
- Wedemeyer H. Hepatitis C. in.: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. edited by Mark Feldman, Lawrence S. Friedman, Laurence J. Brandt. 10th ed. 2015.
- Murray M. P450 enzymes. inhibition mechanisms, genetic regulation and effects of liver disease. Clin. Pharmacokinet. 1992; 23(2): 132-46.
- Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin. Pharmacokinet. 1999; 37(5): 399-31.
- Andersson T., Olsson R., Regardh C.G., Skanberg i. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clin Pharmacokinet1993; 24: 71-8.
- Halilovic J., Heintz B.H. Antibiotic dosing in cirrhosis. Am. J. Health. Syst. Pharm. 2014; 71(19): 1621-34.
- de Boer W.A., Thys J.C., Borody T.J., Graham D.Y., O'Morain C., Tytgat G.N. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur. J. Gastroenterol. Hepatol. 1996; 8(7): 641-43.
补充文件
